Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:2/14/2008

Expects Fiapta(TM) (Iloperidone) PDUFA Action July 27, 2008

Completes Enrollment for VEC-162 Phase III Chronic Insomnia Study

ROCKVILLE, Md., Feb. 14 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced financial and operational results for the fourth quarter and fiscal year ended December 31, 2007.

Vanda reported research and development (R&D) expenses in the fourth quarter of 2007 of $12.6 million, compared to third quarter of 2007 R&D expenses of $13.9 million and fourth quarter of 2006 R&D expenses of $7.9 million. The decrease in R&D expenses between the third and fourth quarters is primarily attributable to costs associated with the ongoing Phase III VEC-162 chronic insomnia clinical trial being offset by a non-recurring third quarter milestone charge of $5.0 million for the Fiapta(TM) New Drug Application (NDA) submission in September 2007. The increase in R&D expenses in the fourth quarter of 2007 relative to the fourth quarter of 2006 is primarily attributable to the same VEC-162 Phase III chronic insomnia clinical trial that was initiated in late 2007. For the full year of 2007, total R&D expenses were $47.2 million compared to $52.1 million during 2006. Total expenses for the fourth quarter of 2007 were $22.0 million, compared to $23.5 million in the third quarter of 2007 and $12.4 million in the fourth quarter of 2006. For the full year of 2007, total expenses were $80.0 million, compared to $65.7 million in 2006.

Net loss was $20.7 million for the fourth quarter of 2007, compared to $21.9 million in the third quar
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vion Pharmaceuticals Holds Special Meeting of Stockholders
2. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
3. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
9. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
10. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Diego, California (PRWEB) April 24, 2015 ... announced key milestones in its allogeneic stem-cell product ... Biopharma to properly reflect the corporate strategic direction. ... our allogeneic (donor) adipose stem cell development program ... completion of our cGMP manufacturing facility and hiring ...
(Date:4/24/2015)... SAN DIEGO , April 24, 2015  Pfenex ... in the development of biosimilar therapeutics including high value ... of its follow-on public offering of 6,000,000 shares of ... of $15.50 per share. Of the shares being offered, ... 3,390,000 shares are being offered by existing stockholders. Pfenex ...
(Date:4/24/2015)... April 24 , 2015 PAREXEL International ... services provider, today announced that Partnerships in Clinical Trials ... Management, the 2015 Clinical Innovator of the Year.  The ... team for the Company,s Perceptive MyTrials ® Data-Driven ... Thursday night during the 2015 Partnership Awards in ...
(Date:4/23/2015)... Athena San Diego, an organization that accelerates ... San Diego’s technology and life science sectors, will announce ... their Gala on April 30, 2015 from 5-9pm at ... http://athenasd.org/events/ , The Pinnacle Awards recognize individuals and ... of fostering networking, risk taking and diversity of thought, ...
Breaking Biology Technology:Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Pfenex Inc. Announces Pricing Of Follow-on Offering 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2
... and BioMed Central are announcing the launch ... today, a new online community for ... opportunities and industry news. (Logo: ... http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO ) (Logo: http://photos.prnewswire.com/prnh/20100916/FL66006LOGO ...
... The PhD thesis by Carlos Echeverra Arrondo, Doctor in ... "On doped semiconductor quantum dots and magnetic nanowires", studied ... The interest aroused by nanoscience and nanotechnology spurred Dr ... their size is reduced to less than one hundred ...
... SIAL ) will be presenting at the UBS ... 12:30 PM ET in New York, NY. Interested parties may ... http://investor.sigmaaldrich.com/ .  Users can click the "Webcast" icon to ... Sigma-Aldrich is a leading Life Science and High Technology ...
Cached Biology Technology:BioSpace and BioMed Central Create Global Career Community 2Ph.D. study of behavior of semiconductor crystals of size less than 100 nanometers 2
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... of the "Global Iris Recognition Market 2015-2019" ... the Global Iris Recognition market to grow at a ... This report covers the present scenario and the ... the period 2015-2019. To calculate the market size, the ...
(Date:3/23/2015)... SoundView Technology Group issues a new research update ... Wocket smart wallet. SoundView was one of the selected user groups ... the Wocket in multiple scenarios and outlets. ... retailers, making both debit and credit card payments.  ... the company meets their plans in 2015, it would push ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... This press release is available in French . ... Cancer (IRIC) of the Universit de Montral have identified a ... the origin of several cancers. In an article published in ... recent discovery of a protein complex that controls the RAS/MAPK ...
... have discovered a disease mechanism that links hereditary amyotrophic lateral ... and points to a possible therapeutic target. The findings ... Nature Neuroscience . ALS is an adult-onset disease ... three to five years of diagnosis. Scott Brady, ...
... accumulating in municipal landfills, and reliance on imported oil ... new ultra-light biodegradable foam plastic material made from two ... The new substance could be used in furniture cushions, ... ACS, Biomacromolecules , a monthly journal. ...
Cached Biology News:Discovery of a mechanism that controls the expression of a protein involved in numerous cancers 2Link between 2 forms of ALS suggests drug target 2Link between 2 forms of ALS suggests drug target 3
...
... Nonanoyl-N-methylglucamide White solid. Water-soluble ... readily removed by dialysis. Useful reagent ... by HPLC. Absorbance (10%, H ... O. CMC 19 - 25 mM. ...
Anti Autotaxin /ENPP2 , - (Rabbit)...
... Tecans MiniPrep series of robotic workstations ... The MiniPrep is the ideal automation ... automation of routine laboratory procedures, improving throughput, ... based Gemini for MiniPrep software allows you ...
Biology Products: